[Management of toxicities of BRAF inhibitors and MEK inhibitors in advanced melanoma].
Gestion des toxicités des inhibiteurs BRAF et MEK dans le mélanome métastatique.
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Azetidines
/ adverse effects
Benzimidazoles
/ adverse effects
Carbamates
/ adverse effects
Drug Combinations
Humans
Imidazoles
/ adverse effects
Melanoma
/ drug therapy
Mitogen-Activated Protein Kinase Kinases
/ antagonists & inhibitors
Mutation
Oximes
/ adverse effects
Piperidines
/ adverse effects
Proto-Oncogene Proteins B-raf
/ antagonists & inhibitors
Pyridones
/ adverse effects
Pyrimidinones
/ adverse effects
Sulfonamides
/ adverse effects
Vemurafenib
/ adverse effects
BRAF inhibitor
Combinaison
Combination
Inhibiteur BRAF
Inhibiteur MEK
MEK inhibitor
Melanoma
Mélanome
Toxicity
Toxicité
Journal
Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
20
10
2020
revised:
17
12
2020
accepted:
24
12
2020
pubmed:
5
4
2021
medline:
28
5
2021
entrez:
4
4
2021
Statut:
ppublish
Résumé
Major therapeutic advances have been made recently in the treatment of metastatic melanoma, due to the development of targeted therapies, namely BRAF and MEK inhibitors, in patients with BRAF V600 mutation. Combinations of vemurafenib+cobimetinib, dabrafenib+trametinib, et encorafenib+binimetinib, evaluated in coBRIM, COMBI-d/COMBI-v and COLUMBUS trials respectively have been approved in this indication. Toxicities induced by combination therapies are different from those reported with monotherapies, in terms of frequency and intensity. Physicians who treat melanoma patients thus face news issues relating to prevention, detection and treatment of these adverse events. This paper summarizes tolerance data from the three pivotal trials (coBRIM, COMBI-v and COLUMBUS) and issues recommendations for the specific management of main toxicities, based on experts' opinion. We discuss dermatological, ophthalmological, cardiovascular, digestive, musculoskeletal, renal and general toxicities and propose a timetable for examinations to be performed before and during treatment.
Identifiants
pubmed: 33812673
pii: S0007-4551(21)00081-3
doi: 10.1016/j.bulcan.2020.12.014
pii:
doi:
Substances chimiques
Azetidines
0
Benzimidazoles
0
Carbamates
0
Drug Combinations
0
Imidazoles
0
Oximes
0
Piperidines
0
Pyridones
0
Pyrimidinones
0
Sulfonamides
0
binimetinib
181R97MR71
Vemurafenib
207SMY3FQT
trametinib
33E86K87QN
encorafenib
8L7891MRB6
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Mitogen-Activated Protein Kinase Kinases
EC 2.7.12.2
cobimetinib
ER29L26N1X
dabrafenib
QGP4HA4G1B
Types de publication
Journal Article
Review
Langues
fre
Sous-ensembles de citation
IM
Pagination
528-543Informations de copyright
Copyright © 2021 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.